|
|||||
|
|
Radioimmunoscintigraphy with technetium-99m-labelled monoclonal antibody,SM3, in gynaecological cancer |
|
| Authors: | M. Granowska K. E. Britton S. J. Mather D. G. Lowe D. Ellison J. Bomanji J. Burchell J. Taylor-Papadimitriou C. R. Hudson J. H. Shepherd |
| Affiliation: | (1) Nuclear Medicine Department, St. Bartholomew's Hospital, EC1A 7BE West Smithfield, London, UK |
| Abstract: | Radioimmunoscintigraphy (RIS) with technetium-99m labelled SM3, a monoclonal antibody reacting with a polymorphic epithelial mucin glycoprotein core antigen, is evaluated. No adverse effects or thyroid uptake were observed. Studies in 45 patients (one twice) had a sensitivity for gynaecological malignancy of 100% (35/35) and a specificity of 73% (8/11), giving an overall accuracy of 93% (43/46). These results have led to the routine adoption of 99mTc RIS in the management of patients suspected of or having primary or recurrent gynaecological cancer.Correspondence to: M. Granowska |
| Keywords: | Gynaecological cancer Radioimmunoscintigraphy Technetium-99m-labelled SM3 monoclonal antibody |
| 本文献已被 SpringerLink 等数据库收录！ | |